Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Hossein Panjideh"'
Publikováno v:
Toxins, Vol 14, Iss 10, p 703 (2022)
The authors wish to make corrections to their paper [...]
Externí odkaz:
https://doaj.org/article/1c95e24a8a6f433e9e4e31f883eda528
Publikováno v:
Toxins, Vol 14, Iss 7, p 478 (2022)
Immunotoxins do not only bind to cancer-specific receptors to mediate the elimination of tumor cells through the innate immune system, but also increase target cytotoxicity by the intrinsic toxin activity. The plant glycoside SO1861 was previously re
Externí odkaz:
https://doaj.org/article/9ecd3bf67ce64b0e9fb6040ef016fbc2
Autor:
Frank Breitling, Gerhard Moldenhauer, Antonio Pezzutto, Oliver Schmetzer, Martin Lipp, Saskia Meyer, Regina Fertig, Hossein Panjideh, Dorothée Deppe, Sandra Lüttgau
Publikováno v:
Antibodies, Vol 2, Iss 2, Pp 338-352 (2013)
Using genetic engineering a humanized Fab fragment with specificity for CD19 was fused to a disulfide-stabilized single-chain antibody (dsFv) recognizing CD5. This format should show reduced immunogenicity and improved tissue penetration. The specifi
Externí odkaz:
https://doaj.org/article/ffd0b440b79a4a5788838607b4cc3b4f
Autor:
Hendrik Fuchs, Nicole Niesler, Alexandra Trautner, Simko Sama, Gerold Jerz, Hossein Panjideh, Alexander Weng
Publikováno v:
Biomedicines, Vol 5, Iss 2, p 14 (2017)
Protein-based targeted toxins play an increasingly important role in targeted tumor therapies. In spite of their high intrinsic toxicity, their efficacy in animal models is low. A major reason for this is the limited entry of the toxin into the cytos
Externí odkaz:
https://doaj.org/article/caa53ba2a27e465b8428a7cbc0edbd5b
Autor:
Gerd Müller, Frank Wilde, Mathias Koch, Hossein Panjideh, Gerhard Moldenhauer, Martin Lipp, Susanne Scheu
Publikováno v:
International Journal of Cancer. 135:2623-2632
Bispecific antibodies are promising agents for immunotherapy. Here, we describe a quadroma-based trifunctional bispecific antibody binding the chemokine receptor CXCR5 and the T-cell antigen CD3 that efficiently prevents tumor growth in a mouse B-cel
Autor:
Antonio Pezzutto, Saskia Meyer, Dorothé e Deppe, Regina Fertig, Sandra Lüttgau, Oliver Schmetzer, Hossein Panjideh, Frank Breitling, Martin Lipp, Gerhard Moldenhauer
Publikováno v:
Antibodies, Vol 2, Iss 2, Pp 338-352 (2013)
Antibodies
Volume 2
Issue 2
Pages 338-352
Antibodies
Volume 2
Issue 2
Pages 338-352
Using genetic engineering a humanized Fab fragment with specificity for CD19 was fused to a disulfide-stabilized single-chain antibody (dsFv) recognizing CD5. This format should show reduced immunogenicity and improved tissue penetration. The specifi
Autor:
Christopher Bachran, Patricia Fasold, Peter M. Deckert, Hendrik Fuchs, Diana Bachran, N. Schellmann, Hossein Panjideh
Publikováno v:
Journal of Immunotherapy. 35:570-578
In adults, endothelial cell division occurs only in wound healing, during menstruation, or in diseases such as wet age-related macular degeneration or development of benign or malignant tissues. Angiogenesis is one of the major requirements to supply
Autor:
Vânia Coelho, Ulrich Keilholz, Eckhard Thiel, Hendrik Fuchs, P. Markus Deckert, Hossein Panjideh, Jens Dernedde
Publikováno v:
Bioprocess and Biosystems Engineering. 31:559-568
Recombinant antibody fusion constructs with heterologous functional domains are a promising approach to new therapeutic targeting strategies. However, expression of such constructs is mostly limited to cost and labor-intensive mammalian expression sy
Autor:
Hossein Panjideh, Gerold Jerz, Alexander Weng, Nicole Niesler, Hendrik Fuchs, Simko Sama, Alexandra Trautner
Publikováno v:
Biomedicines, Vol 5, Iss 2, p 14 (2017)
Biomedicines
Biomedicines
Protein-based targeted toxins play an increasingly important role in targeted tumor therapies. In spite of their high intrinsic toxicity, their efficacy in animal models is low. A major reason for this is the limited entry of the toxin into the cytos
Autor:
Hossein, Panjideh, Gerd, Müller, Mathias, Koch, Frank, Wilde, Susanne, Scheu, Gerhard, Moldenhauer, Martin, Lipp
Publikováno v:
International journal of cancer. 135(11)
Bispecific antibodies are promising agents for immunotherapy. Here, we describe a quadroma-based trifunctional bispecific antibody binding the chemokine receptor CXCR5 and the T-cell antigen CD3 that efficiently prevents tumor growth in a mouse B-cel